Treatment of Resectable Malignant Brain Tumors

Stopped early · Phase 4

Conditions studied: Brain Tumor

In brief

The goals of this study are to evaluate each of the following items: 1. Time to recurrence in patients receiving brachytherapy with the GliaSite RTS 2. Overall survival (OS) in patients with malignant brain tumors who are undergoing surgical resection and brachytherapy treatment with the GliaSite® Radiation Therapy System (RTS). 3. Incidence of serious adverse events in patients treated with GliaSite RTS

Key facts

Study ID

NCT00415467

Run by

M.D. Anderson Cancer Center

People needed

13

Starts

2005-01-01

Expected to finish

2008-07-01

Last updated by the study team

2012-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient must have histologically proven malignant brain tumor
• Patient must be a candidate for surgical resection of the tumor mass.
• Patient must not be pregnant or breast-feeding. All patients with the potential for pregnancy should be counseled and requested to follow acceptable birth control methods to avoid conception.
• Patient must sign informed consent form

You may not qualify if…

• Serious concurrent infection or medical illness which could jeopardize the ability of the patient to receive the GliaSite catheter with reasonable safety.

Where it is running

• U.T.M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.